The percentage of CD14++CD16+ monocytes is slightly, but significantly, higher in CKD and PD patients (p < 0.05) and more than twofold higher in patients on hemodialysis (HD) vs. healthy control (Ctrl) (p < 0.01) with a corresponding decrease in CD14++CD16− (p < 0.01) and increase in CD14+CD16++ monocytes in HD (P < 0.01). Here, CD14 is linked to chronic kidney disease.